News & articles
SemaglutideLong-acting GLP-1 analog for appetite regulation and sustained metabolic support. A cornerstone in body-composition and weight-management programs.
FDA Approves MIMRYLO (Rusfertide), a Hepcidin-Mimetic Peptide for Polycythemia VeraThe FDA approved rusfertide (MIMRYLO) on August 28, 2026 for polycythemia vera patients needing frequent phlebotomy—marking the first hepcidin-mimetic peptide therapy in the United States.
- GLP-1 Bulk-Drug Comment Period Closes; Thousands of Filings on 503B Peptide Access
FDA logged roughly 3,900 public comments by the July 30, 2026 deadline on whether GLP-1 bulk substances belong on the 503B bulks list—one of the agency's busiest compounding dockets ever.
- Lilly Reports Phase 3 TRIUMPH Data for Retatrutide, a GLP-1/GIP/Glucagon Triple Agonist
Eli Lilly's July 2026 TRIUMPH Phase 3 topline showed retatrutide produced up to 28.7% mean weight loss at 68 weeks in obesity patients without diabetes, sending ripples through the peptide supply chain.
- Ketone Esters Plus Semaglutide: Preclinical Data on Muscle Preservation Draws Attention
Researchers reported in June 2026 that (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone ester co-administration attenuated lean-mass loss in semaglutide-treated rats without blocking fat reduction.
- ENDO 2026: GLP-1 and Multi-Agonist Peptides Dominate Chicago Readouts
ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.